Oncolytics Biotech Inc. (ONCY)

[onco_investor]

Listen to today's clinical update conference call w/Q&A

http://www.integratir.com/presentations.asp?ticker=t.onc

Conference Call Details
Dr. Brad Thompson, President and CEO of Oncolytics, will host a conference call and webcast today, February 16th, 2010 at 2:00 p.m. MT (4:00 p.m. ET) to update investors on the Company’s ongoing clinical program for REOLYSIN. To access the conference call by telephone, dial 1-647-427-7450 or 1-888-231-8191. A live audio webcast will also be available at the following link: http://www.newswire.ca/en/webcast/viewEvent.cgi?eventID=2967140 or through the Company’s website at www.oncolyticsbiotech.com. Please connect at least 15 minutes prior to the webcast to ensure adequate time for any software download that may be needed. A replay of the webcast will be available at www.oncolyticsbiotech.com and will also be available by telephone through February 23rd, 2010. To access the telephone replay, dial 1-416-849-0833 or 1-800-642-1687 and enter reservation number 57104101#.


http://www.integratir.com/newsrelease.asp?news=2131023165&ticker=T.ONC&lang=EN&ny=on

Some highlights for me....
I listened to this call and came away very impressed with the Q&A from Rodman and Renshaw who recently downgraded the company, David Miller and others. It was interesting to hear about the planned H&N Phase III trial timeline details and how they are fast tracking getting trial sites up and running in the EU/Belgium while starting the US enrollment sites. We heard about the plan for between 25 and 50 clinical trial sites being utilized to minimize the trial length. We also heard there has been interest from "additional" trial locations in the UK and US that apparently want "in on the testing".

The plan that was laid out for this H&N trial as I heard it was to enroll 80 patients in approx 8-10 months, (4 per site based on 20 initial sites at 2-2-1/2 months per patient)plus 6 months data analysis should get you to 14-16 months from lets say May this year. This puts us somewhere at July 2011 conservatively.

We also heard about "active" partnership talks with parties that fall into three categories. 1. Partner before data is known 2. Partner when interim data is known and 3. Partner when full data is known and analyzed. Brad indicated that most of the interested partners were in category 1 or 2 as he alluded that the required partnership price would likely be higher as risk of approval is reduced as full data is known. He also said that all parties with signed Non-disclosure agreements have access to trial data in near RealTime so any partnership offers would be flowing during the next 2 - 14 months. The real key here is how much the offer's are and how much we are willing to take. Should make for a very interesting upcoming remainder of 2010.

Other update was that some of the interested potential partners were more interested in the NSCLC clinical trial and he outlined the progress of this trial as well. A very good update.